Finance

Annual Report 2005 of Beximco Pharmaceuticals Limited

Annual Report 2005 of Beximco Pharmaceuticals Limited

It is a broadly described annual report of Beximco Pharmaceuticals Limited in the year of 2005. During the year, the company attained net sales of Taka. 3,327.02 million as against Taka. 2,402.70 representing significant 38% overall growth. The Company exports reached Taka. 88.86 million as compared to Taka. 79.49 million of the prior year. Profit before tax and contribution to Workers’ Profit Participation fund increased by 37.9% to Taka. 509.63 million (21.4% increase on a pro-forma basis). Earnings per share stood at Taka. 6.36 as against Taka. 4.71 of the previous year.

The Board of Directors has recommended 15% cash dividend for shareholders’ approval for the year ended 31st December 2005. These financial statements are presented in Bangladesh Taka (Taka/Tk/BDT) which is the company’s functional currency. All financial information presented in Taka has been rounded off to the nearest Taka.

More Annual Report of Beximco Pharmaceuticals Limited :

  1. Annual Report 2001 of Beximco Pharmaceuticals Limited
  2. Annual Report 2002 of Beximco Pharmaceuticals Limited
  3. Annual Report 2003 of Beximco Pharmaceuticals Limited
  4. Annual Report 2004 of Beximco Pharmaceuticals Limited
  5. Annual Report 2005 of Beximco Pharmaceuticals Limited
  6. Annual Report 2006 of Beximco Pharmaceuticals Limited
  7. Annual Report 2007 of Beximco Pharmaceuticals Limited
  8. Annual Report 2008 of Beximco Pharmaceuticals Limited
  9. Annual Report 2009 of Beximco Pharmaceuticals Limited
  10. Annual Report 2010 of Beximco Pharmaceuticals Limited
  11. Annual Report 2011 of Beximco Pharmaceuticals Limited
  12. Annual Report 2012 of Beximco Pharmaceuticals Limited
  13. Annual Report 2013 of Beximco Pharmaceuticals Limited
  14. Annual Report 2014 of Beximco Pharmaceuticals Limited
  15. Auditors’ Report 2015 of Beximco Pharmaceuticals Limited
  16. Annual Report 2016 of Beximco Pharmaceuticals Limited
  17. Auditors’ Report 2017 of Beximco Pharmaceuticals Limited